What Is DHT Cream and How Does It Work?

DHT cream is a topical medication containing dihydrotestosterone, a naturally occurring androgen that binds to hormone receptors more tightly and potently than testosterone itself. Applied directly to the skin, it delivers DHT into the body without the need for injections or oral medications. Doctors have prescribed it mainly for two conditions: micropenis in children and gynecomastia (abnormal breast tissue growth) in men. The cream sits in an unusual spot in medicine, widely studied in certain clinical contexts but unavailable in many countries, and its biology reveals some surprising twists about how androgens work in the body.

How DHT Differs from Testosterone

Your body produces DHT from testosterone through the action of an enzyme called 5-alpha reductase. In tissues where that enzyme is active, such as the skin, hair follicles, and genitals, testosterone gets converted into DHT locally. What makes DHT distinctive is the way it locks onto androgen receptors. Research on receptor binding shows that testosterone separates from the androgen receptor about three times faster than DHT does, and DHT is also better at stabilizing the receptor once bound.¹ In practical terms, this means DHT sends a stronger, longer-lasting signal to the cells it reaches.

There is another critical difference. Testosterone can be converted into estradiol (an estrogen) by a different enzyme called aromatase. DHT cannot be aromatized into estrogen. This matters clinically because some effects doctors want from androgen therapy, like genital growth or breast tissue reduction, benefit from a strong androgen signal without an accompanying rise in estrogen. That is exactly what DHT cream provides.

What the Cream Looks Like in Practice

DHT cream, sometimes labeled as Andractim in markets where it is available, is a gel or cream formulation applied to the skin. The DHT absorbs through the skin into the bloodstream or acts locally on the tissue where it is applied, depending on the goal. Concentrations typically used in clinical studies have been around 2.5% DHT in a gel base, though formulations have varied across different research groups.

One thing worth understanding about transdermal androgen delivery in general: gels and creams produce different hormonal profiles than patches or injections. A pharmacokinetic study comparing transdermal testosterone products found that gel formulations produced DHT levels and DHT-to-testosterone ratios that were two to three times higher than those from patches.² That elevated DHT conversion with skin-applied testosterone gels is actually part of why a dedicated DHT cream exists: it cuts out the middleman and delivers the target hormone directly.

Treating Micropenis in Children

The most thoroughly studied use of DHT cream is for micropenis, a condition defined as a stretched penile length more than 2.5 standard deviations below the mean for age. Treatment during infancy or childhood can promote penile growth before puberty, potentially avoiding more invasive interventions later. Multiple clinical studies have documented meaningful responses.

A comparative randomized study treated infants with micropenis using transdermal DHT and found that the mean penile length increased from about 2.9 cm to 5.3 cm after an average of roughly 65 days of treatment, a gain of about 2.4 cm.³ Another study following children from different genetic backgrounds tracked growth over six months and saw progressive increases from a baseline average of about 1.7 cm to 2.9 cm at six months.⁴ The range of responses varies by age and the underlying cause of the micropenis.

DHT cream has also been used specifically in children with partial androgen insensitivity syndrome, a condition in which the body’s androgen receptors do not respond fully to normal levels of testosterone. In a case series covering patients treated before, during, and after puberty, prepubertal and peripubertal patients saw gains of 40% and 63% in stretched penile length, respectively.⁵ The fact that DHT cream worked even in patients whose receptors are partly resistant underscores how much more potent DHT is at the receptor compared to testosterone.

Treating Gynecomastia in Adults

Gynecomastia, the development of breast tissue in men, can be driven by an imbalance between estrogen and androgen activity. Because DHT is a pure androgen that cannot convert to estrogen, applying it topically offers a way to shift that balance. A case report published in a clinical infectious diseases journal documented four patients who developed gynecomastia as a side effect of antiretroviral therapy for HIV, and all four were successfully treated with percutaneous DHT gel.⁶

This application highlights a key advantage of DHT over testosterone for breast tissue specifically. If you give a man testosterone to counteract gynecomastia, some of that testosterone will aromatize into estrogen, which can actually feed the breast tissue growth you are trying to reverse. DHT sidesteps that problem entirely. The evidence base for this use remains small, mostly case series and reports rather than large trials, but the biological rationale is sound and the results have been consistently positive in the published cases.

Sexual Function and Mood

A common assumption is that androgens are the primary driver of libido in men, and since DHT is the most potent androgen, it should be a powerful libido enhancer. The reality, based on the best available trial data, is more nuanced. A 24-month placebo-controlled trial in healthy older men found that DHT treatment increased blood levels of DHT while completely suppressing testosterone, estradiol, and the pituitary hormones that stimulate their production. Despite these dramatic hormonal shifts, DHT had no measurable effect on 33 separate measures of sexual function and mood, with one exception: a mild but statistically significant decrease in overall sexual desire, which reversed after the men stopped treatment.⁷

This finding challenges the idea that more potent androgen means more desire. It also demonstrates something researchers have debated for years: that aromatization of testosterone into estradiol may play a role in male sexual desire, since DHT suppressed estradiol entirely and desire ticked down slightly. The take-home message is that DHT cream is not a libido booster. It maintains sexual function in the absence of testosterone, which is itself a notable finding, but it does not enhance it.

Side Effects and Skin-Related Concerns

Because DHT is active in the skin, side effects related to the skin surface are a legitimate concern. DHT stimulates sebaceous glands, the tiny oil-producing glands in your skin that are central to acne development. Laboratory research on cultured sebocytes (the cells that make up sebaceous glands) found that adding DHT upregulated inflammatory molecules, specifically interleukin-6 and tumor necrosis factor-alpha.⁸ The researchers concluded that DHT is involved not just in increasing oil production but also in triggering the inflammatory cascade that turns a clogged pore into an active acne lesion. In clinical practice, increased oiliness and acne at or near the application site are among the reported side effects of DHT cream, though their severity varies.

The relationship between DHT and hair is more complex than “DHT causes hair loss” suggests. On the scalp, DHT acts on hair follicles to shorten the growth phase and shrink the follicle over time, a process called miniaturization. An animal study using mice found that DHT induced early hair regression, hair miniaturization, and loss of hair density, effects that could be partly reversed by blocking the androgen receptor with a drug called bicalutamide.⁹ For men already genetically predisposed to androgenetic alopecia (male pattern baldness), adding exogenous DHT through a cream could theoretically accelerate thinning. The irony is that while DHT shrinks hair follicles on the scalp, it stimulates hair growth in other areas like the beard and chest. This tissue-specific response to the same hormone is one of the stranger quirks of androgen biology.

What Happens to the Prostate

Prostate tissue is loaded with 5-alpha reductase, and DHT is known to be the dominant androgen inside the prostate gland. This makes the prostate a natural concern when giving someone extra DHT. However, one of the more counterintuitive findings in this area comes from a randomized controlled trial in healthy men who received daily transdermal DHT gel for 28 days. Their blood DHT levels rose nearly sevenfold. Yet when the researchers biopsied the prostate tissue directly, they found no difference in intraprostatic DHT or testosterone concentrations between the treatment group and the placebo group. Prostate volume, prostate-specific antigen (PSA, the blood marker used to screen for prostate problems), cell proliferation, and androgen-regulated gene expression were all unchanged.¹⁰

The explanation appears to be that the prostate maintains its own internal androgen environment through local enzyme activity, and flooding the bloodstream with DHT does not override that internal regulation, at least over a one-month period. This is a reassuring short-term finding, but it comes with an important caveat: 28 days is a brief window. Long-term prostate safety data for exogenous DHT therapy remain limited, and no one should interpret this single trial as proof that prolonged DHT cream use is safe for the prostate. It does, however, suggest that the prostate is not as passively responsive to circulating DHT as the straightforward “DHT drives prostate growth” narrative implies.

Why DHT Cream Is Hard to Get

If you have gone looking for DHT cream, you have probably noticed it is not sitting on pharmacy shelves in most countries. Andractim, the most well-known brand, has been available primarily in France and a few other European markets. It has never been approved by the FDA in the United States. Doctors in the U.S. and elsewhere who want to prescribe topical DHT typically need to work with compounding pharmacies, which make the formulation on a custom basis. This makes access inconsistent and quality variable, since compounding pharmacies are not held to the same manufacturing standards as large pharmaceutical companies.

Part of the reason DHT cream has not gained wider regulatory approval is that testosterone, which is far more commercially established, can accomplish many of the same goals, even if not always as efficiently. The clinical niches where DHT offers a clear advantage over testosterone, like micropenis in certain androgen insensitivity syndromes and estrogen-driven gynecomastia, are small patient populations that do not attract the kind of pharmaceutical investment needed for large-scale approval trials.

DHT Cream and Bone Density

Testosterone’s effects on bone are well established, but DHT’s role has been less clear because DHT cannot be aromatized into estrogen, and estrogen is a major player in maintaining bone density in both men and women. Animal research in ovariectomized rats found that the highest dose of DHT increased bone mineral density relative to controls and even to the estrogen-treated group, though by a different mechanism: estrogen preserved bone by slowing bone breakdown, while DHT increased bone mass by promoting bone growth and new bone formation.¹¹

The human picture is less encouraging, at least when DHT is used alone. The same 24-month trial in older men mentioned earlier found that DHT administration, which suppressed estradiol by blocking its precursor testosterone, resulted in reduced spinal bone density.⁷ In other words, whatever bone-building effect DHT may have on its own was not enough to offset the loss of estrogen’s bone-protective action in these men. For anyone considering long-term DHT therapy, bone density monitoring would be a sensible precaution, especially in older adults who are already at risk of osteoporosis.

Detection in Anti-Doping Testing

DHT is classified as a prohibited substance by the World Anti-Doping Agency. Athletes who use it, whether as a cream or any other formulation, face suspension. The detection methods rely on the fact that exogenous DHT shifts the ratios of various urinary hormones in predictable ways. An early study on this found that even modest doses of DHT increased urinary excretion of DHT and two of its metabolites relative to testosterone and other hormones, while blood concentrations of testosterone and pituitary hormones like LH and FSH dropped.¹² The suppression of LH and testosterone in the presence of elevated DHT metabolites creates a hormonal fingerprint that is difficult to explain away as natural variation. Modern anti-doping labs use these ratio-based methods alongside direct measurements, making DHT use one of the more detectable forms of androgen doping.

The fact that anti-doping agencies specifically test for DHT reflects a real concern: because DHT is a more potent androgen than testosterone at the receptor level and acts on muscle, skin, and other tissues, it has potential for misuse in sport. Athletes occasionally seek it out under the mistaken belief that topical application might evade testing, but the urinary metabolite profile gives it away regardless of the delivery route.